摘要
细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂是治疗激素受体阳性乳腺癌的抗肿瘤药物,其中,哌柏西利、阿贝西利和达尔西利已在中国获得批准用于乳腺癌的治疗。CDK4/6抑制剂常见的不良反应包括骨髓抑制、胃肠道不良反应、肝功能异常、皮肤及皮下组织不良反应等。中国临床肿瘤学会乳腺癌专家委员会共识专家组总结了CDK4/6抑制剂常见不良反应的发生率、临床表现和严重程度分级,结合临床经验并参考国内外研究进展,制定了不良事件的管理措施,形成乳腺癌CDK4/6抑制剂相关性不良反应管理共识,旨在从不良反应管理角度更好地指导临床实践,帮助选择CDK4/6抑制剂最佳治疗方案。
Cyclin-dependent kinases 4/6(CDK4/6)inhibitors are anti-tumor agents for the treatment of hormone receptor-positive breast cancer.Palbociclib,abemaciclib and dalpiciclib have been approved for the treatment of breast cancer in China.Common adverse effects of CDK4/6 inhibitors include bone marrow suppression,gastrointestinal toxicities,liver dysfunction,and skin or subcutaneous tissue adverse reactions(AEs).The Breast Cancer Expert Group of Chinese Society of Clinical Oncology(CSCO)summarized the incidence,clinical manifestations,and grading of the AEs.This expert consensus reports measures of AE management on the basis of experience of clinical practice and the latest advances worldwide,aiming to guide clinical practice by the way of managing AE and help to choose the best treatment regimen.
作者
葛睿
王碧芸
江泽飞
中国临床肿瘤学会乳腺癌专家委员会共识专家组
Ge Rui;Wang Biyun;Jiang Zefei;Expert Group of Chinese Society of Clinical Oncology Breast Cancer(Department of General Surgery,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Department of Medical Oncology,Cancer Hospital Affiliated to Fudan University,Shanghai 200032,China;Department of Breast Oncology,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;不详)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2022年第12期1296-1304,共9页
Chinese Journal of Oncology
